Reporter brief
Senolytics as a Novel Treatment for Interstitial Lung Disease in Common Variable Immunodeficiency (CVID)
What happened
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract provides no efficacy data, making it impossible to determine whether fisetin had any effect on CVID-related lung disease.
- It is unclear whether this trial was completed, what outcomes were measured, or whether results favoured the intervention or placebo.
- No information is available on safety, tolerability, or suitability for clinical use.
Study design and sample
Rct; Human.
Common variable immunodeficiency (CVID) patients with interstitial lung disease
- Design
- Rct
- Sample
- —
- Journal
- Avni Joshi
- Published
- Jun 30, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.